Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab.

Mimori, Masahiro; Komatsu, Teppei; Maku, Takahiro; Mitsumura, Hidetaka; Iguchi, Yasuyuki

Mimori, Masahiro; Komatsu, Teppei; Maku, Takahiro; Mitsumura, Hidetaka; Iguchi, Yasuyuki.

Mimori M; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan. mr.gaspard.de.la.nuit@gmail.com.
Komatsu T; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Maku T; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Mitsumura H; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Iguchi Y; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.

Neurol Sci ; 43(7): 4081-4083, 2022 Jul.

Article in English | MEDLINE | ID: covidwho-1777738

ABSTRACT

ABSTRACT

Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was continued for MG after contracting COVID-19, followed by a favorable outcome.

Subject(s)

COVID-19; Myasthenia Gravis; Antibodies, Monoclonal, Humanized/therapeutic use; Complement Inactivating Agents/therapeutic use; Humans; Myasthenia Gravis/complications; Myasthenia Gravis/drug therapy

Keywords

COVID-19; Eculizumab; Myasthenia gravis

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Myasthenia Gravis Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Neurol Sci Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: S10072-022-05922-2

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google